Perspective evaluates opportunities and limitations for mRNA tuberculosis vaccines, highlighting strategies to optimize delivery and lung-localized immunity.
Key Points
Examine the biological challenges of tuberculosis vaccine development and evaluate strategies to optimize mRNA platforms for protective immunity against Mycobacterium tuberculosis.
Perspective review synthesizing biological mechanisms of Mycobacterium tuberculosis infection and host immune protection.
Evaluation of mRNA vaccine design, formulation parameters, and delivery pathways required for systemic and mucosal immune responses.
mRNA platforms induce potent systemic humoral and effector immune responses that provide distinct advantages for tuberculosis vaccine design.
Current formulations demonstrate limited induction of lung-localized mucosal immunity, presenting a key hurdle for tuberculosis protection.
Optimizing antigen selection, lipid nanoparticle formulation, and respiratory delivery routes is essential to achieve robust local protection.